Organoids are the self-organizing microscopic3D structures grown from the stem cells in vitro. This innovation has impelled the development of a few novel human-cancer models. The organoids are progressively utilized in various uses, including disease modelling, pathogenesis, drug screening and regenerative medicine. In the traditional method of research in human developmental biology, 3D cell cultures and organoids are increasingly replacing 2D cell cultures. The requirement for novel drugs is growing significantly owing to the increasing cases of cancer and this is escalating the scope of application of the organoids in the oncology research.
Furthermore, technological advancements in this field and increasing inclination towards the personalized medicines is propelling the market growth of organoids market. However, the higher investment of money and time to discover the effective functioning of the organoids is hindering the market growth of organoids market.
The global organoids market is expected to grow at a compound annual growth rate (CAGR) of around 20.9% over the period of next 5 years.
The growth of organoids market are attributed to the key factors such as increasing research and development and rising bio-banking activity. As per the Humane Society International, over 115 million animals are used in laboratories for research across the world every year. The organoids are estimated to substitute the animals for testing in the laboratories. Thus, growing focus of substituting the animal models for research with the advancement of commercially available organoids is boosting the organoids market growth. In the last few years, there is highly demand from biopharmaceutical industry. For instance, according to India Brand Equity Foundation, the Indian biotechnology industry was worth US$ 63 billion in 2019 and is expected to develop at a CAGR of 10.9 percent to US$ 102 billion by 2025. The Indian biotechnology industry is forecast to increase its share of the global biotechnology market to 19% by 2025, up from 3% in 2017. Biopharmaceuticals, which accounted for 58 percent of the Indian biotechnology industry in 2019, is led by bio-agriculture, which accounted for 19 percent, and bio-services, which accounted for 15%. From 2019 to 2025, the Indian biologics market is forecast to develop at a CAGR of 22%, reaching US$ 12 billion. Hence, rise demand from biotechnology industry are likely to be prime driver for market growth.
ORGANOIDS MARKET SEGMENTATION:
- Pluripotent Stem Cells
- Organ-Specific Adult Stem Cells
By Product Type:
- Intestinal Organoids
- Neural Organoids
- Pancreatic Organoids
- Hepatic Organoids
- Colorectal Organoids
- Biomedical Research and Drug Discovery
- Regenerative Medicine
- Therapeutic Tools
- Cancer Research
- Biopharmaceutical Companies
- Academics and Research Institutes
- Contract Research Organizations
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
North America is projected to gain dominance in the organoids market. The market growth in this region can be attributed to the rising number of patients suffering from several diseases, commercialization of the organoids models & stem cell research and increasing investment in the research and development. Higher penetration of the human organoids technology among the key end users such as pharmaceuticals, biotechnology companies, academia, CROs and well established distribution channels for the human organoids product suppliers and manufacturers is driving the North America organoids market growth. Easy accessibility and higher adoption of developed technologies owing to the significant per-capita healthcare expenditure by Canadian and the U.S. governments and supportive government regulations are propelling the growth of organoids market in this region.
Asia Pacific is anticipated to exhibit the fastest growth of organoids market in the future years. This owes to various factors such as increasing adoption of tumor modelling and bio-banking activity and alternatives of animal testing model acting as the kingpins are anticipated to augment the growth of the organoids market. Owing to the consistent advancements, tumouroid lines are being passed in vitro and opens new avenues for various downstream applications.
FEW KEY PLAYERS IN ORGANOIDS MARKET:
- STEMCELL Technologies, Inc.
- Cellesce Ltd.
- Hubrecht Organoid Technology
- 3Dnamics, Inc.
- Organoid Therapeutics
- PeproTech, Inc.
- Thermo Fisher Scientific
- Corning Incorporated (Life Sciences)
- Merck KGgA
-In January 2021, Upcyte Technologies GmbH entered into a partnership with BIOIVT for the exclusive distribution of its cell products across the globe. This would help in the expansion of the product portfolio of the company and enhance their customer base.
-In September 2020, BGI-Qingdao and Ubrecht Organoid Technology (HUB) signed a Memorandum of Understanding for forming a collaboration to establish the joint Next Generation Diagnostics center for better cure and treatments, to improve the personalized care and faster development of new medicines in China.
-In March 2020, UPM Biomedicals and Nichirei Biosciences collaborated together for giving the UPM Biomedicals culture products in Japan. This collaboration upgraded the availability of normal hydrogels for the organoid culture. This strategy would help in the overall development of the companies.
Get a brochure of this research study Click Here